A weight loss program that merely classifies its users by age group, body type, or declared activity level is only engaging in marketing segmentation. Clinical personalization begins where these criteria stop: metabolic history, ongoing treatments, cardiovascular comorbidities, thyroid status, sleep quality. We regularly observe protocols labeled “customized” that do not take any of these variables into account.
Clinical personalization versus marketing segmentation: the criteria that make the difference
The distinction between truly individualized support and a commercial orientation questionnaire lies in the depth of the initial assessment. A form that asks for weight, height, target weight in kilos, and number of meals per day produces a generic profile. It lacks the data that condition the physiological response to caloric restriction.
An actionable personalized assessment includes at least:
- The complete weight history (variations, previous diets, weight regain) and any associated eating disorders
- Diagnosed chronic conditions: type 2 diabetes, metabolic syndrome, hypertension, sleep apnea, joint diseases limiting mobility
- Current pharmacological treatments, including those that promote weight gain (corticosteroids, certain antidepressants, beta-blockers)
- Recent biological markers: fasting blood glucose, lipid profile, TSH, creatinine to assess renal function before any significant protein modification
The HAS reminds us that obesity is a chronic and multifactorial disease, whose management also aims at cardiovascular, metabolic, and functional health. Reducing personalization to a choice among three standard menus ignores this clinical reality.
We recommend checking whether the consulted program requires a medical certificate or a recent blood test before any registration. The absence of this step is a reliable signal of superficial segmentation. The weight loss programs on Viva Médical illustrate this logic of structured support, where the health aspect precedes the dietary aspect.
GLP-1 analogs in weight loss journeys: regulatory framework and misuse risks
The arrival of GLP-1 analogs (Wegovy, Mounjaro, Saxenda) has changed the landscape of personalized programs. Since June 2025, the prescription of these molecules can be done by any doctor in France, respecting the indications and marketing authorization. This opening facilitates access but increases the risk of inappropriate prescriptions.
Current recommendations reserve these treatments for second-line use. Specifically, they are only considered when nutritional measures and physical activity have not produced sufficient results, and according to precise medical criteria.
Titration speed: a blind spot in commercial programs
The rate of dose increase is a risk factor rarely addressed in marketing content. A titration that is too rapid amplifies digestive side effects (nausea, vomiting, diarrhea) and can lead to treatment abandonment. Validated protocols provide for gradual increments over several weeks.
Some online programs incorporate these molecules as a selling point without mentioning the constraints of biological monitoring or formal contraindications (history of pancreatitis, medullary thyroid carcinoma).
A serious personalized program that offers or supports treatment with aGLP-1 must include regular medical follow-up, documented dose adjustment, and periodic reevaluation of the benefit-risk balance.
Meal composition and caloric deficit: adapting the nutritional protocol to individual markers
Most mainstream weight loss programs set a standard caloric deficit, often identical for all profiles at the same “level.” This approach ignores the variability of basal metabolism, which depends on lean mass, age, hormonal status, and restriction history.
An overly aggressive deficit in someone who has already undergone several diets causes a metabolic adaptation that hinders weight loss and promotes regain. We recommend a moderate deficit, recalculated every four to six weeks based on changes in body composition, not just weight on the scale.
Protein intake and renal function
Increasing protein intake is a classic lever to preserve muscle mass during weight loss. High-protein diets are included in most weight loss boxes and online programs.
However, a high protein intake requires proper renal function. In at-risk individuals (long-standing diabetes, poorly controlled hypertension, history of lithiasis), creatinine testing and calculation of glomerular filtration rate must precede any significant increase in dietary protein. A program that does not ask this question is not personalized: it applies a one-size-fits-all scheme with cosmetic variations.
Monitoring weight loss: relevant indicators beyond the scale
Total weight remains the most used indicator by weight loss programs, primarily because it is simple to measure. It is also the least informative when taken in isolation. A rapid loss of several kilos in the first week generally indicates water and glycogen depletion, not fat loss.
Indicators that document a real evolution of the silhouette are waist circumference (correlated with cardiovascular risk), the fat mass/lean mass ratio measured by bioelectrical impedance, and the evolution of functional strength. A good program tracks body composition, not just weight.
The weekly assessment should also include structured subjective parameters: sleep quality, perceived energy level, frequency of food cravings. This data guides nutritional adjustments and allows for early detection of any drop-off.
The sustainable transformation of a silhouette relies on a protocol that evolves with the patient, not on a fixed twelve-week plan. When the program does not include any mechanism for clinical reevaluation, personalization stops at the registration form.
